N4 Pharma Plc (N4P.L)

0.8000 0.0000 (0.00%) At close: 02:02PM BST

N4 Pharma Plc

60 Gracechurch Street
6th Floor
London EC3V 0HR
United Kingdom
44 1332 690061
https://www.n4pharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 5

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Nigel James Theobald	Founder, CEO & Executive Director	82.5k	N/A	1964
Dr. David Templeton	Executive Director & Technical Director	49.5k	N/A	1952
Mr. Luke Sebastian Cairns	Executive Director	44k	N/A	1978
Rob Harris	Head of CMC Development	N/A	N/A	N/A
Dr. Andrew Leishman	Consultant	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.

Corporate governance

N4 Pharma Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.